Stockholm - Stockholm Delayed Price. Currency in SEK
156.00+0.60 (+0.39%)
At close: 11:29 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close155.40
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market Cap57.01B
P/E Ratio (ttm)45.94
Avg Vol (3m)704,436
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Barrons.com11 days ago

    The Downside of Mylan's EpiPen Settlement

    Shares of Mylan (MYL) jumped from roughly $36 to $39 after the maker of the EpiPen reached a settlement with the U.S. Justice Department last week. Analysts Jessica Gladstone and Peter Abdill write: The settlement involves a $465 million payment, which – though significant – is manageable in the context of Mylan's size and liquidity. It will reduce Mylan's cash that would otherwise be available for deleveraging.

  • Market Realist2 months ago

    Why Is Mylan Trading at Lower Valuation Multiples than Its Peers?

    On August 12, 2016, Mylan (MYL) was trading at a forward price-to-earnings (or PE) multiple of about 7.9x.

  • Reuters3 months ago

    Mylan gets EU approval for Meda purchase, subject to conditions

    EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets. Reuters last week reported that Mylan was set to get the green light after offering concessions. The Commission said it had identified 15 markets where it had competition concerns, because of the strong position of the two companies and the lack of sufficient alternatives.